Talphera Posts Q3 Loss, Seeks FDA Nod to Close NEPHRO Enrollment Early
TLPH sits 50% above its 52-week low of $0.687.
Summary
Talphera reported a $4.0 million Q3 net loss and $14.2 million in cash, and said it has asked the FDA to allow an early close of NEPHRO CRRT enrollment at December 31, 2026; peak sales for nafamostat are now estimated above $200 million.
Key Events · Earnings and Guidance · TLPH
-
FDA Briefing Filed for Early Enrollment Close
Talphera has submitted a briefing document asking the FDA to allow NEPHRO CRRT enrollment to close as of December 31, 2026, even if fewer than the targeted 70 patients are enrolled.
-
Enrollment Past 75% With 80%+ Power
More than 75% of the planned 70 patients are enrolled, and the study already exceeds 80% statistical power for the primary endpoint — the basis for the early-close request.
-
Q3 Net Loss of $4.0 Million
Net loss was $4.0 million, or $0.05 per share, versus $4.4 million, or $0.11 per share, in Q3 2025; combined R&D and SG&A rose to $4.1 million from $3.4 million.
-
Cash Falls to $14.2 Million
Cash and investments stood at $14.2 million at September 30, 2026, down from $20.4 million at December 31, 2025, against a going-concern warning previously disclosed in the Q2 10-Q.
Analysis · TLPH · Life Sciences
Cash is the pressure point: Talphera burned $4.0 million in Q3 and ended September with $14.2 million in cash and investments, down from $20.4 million at year-end 2025. At the current spend rate that is roughly three to four quarters of runway, against a going-concern warning previously disclosed in the Q2 10-Q. The offsetting news is regulatory. Enrollment has passed 75% of the planned 70 patients and the study already carries over 80% statistical power, so the company has asked the FDA to let it stop enrolling as of December 31, 2026 even if it falls short of 70. Updated market research also lifted the nafamostat CRRT peak sales estimate above $200 million. Separately, the company flagged that it will file a new S-3 shelf to replace the one expiring November 30, 2026 — a routine step, but one that keeps the door open to raising the cash it needs to fund a PMA filing.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLPH was trading at $1.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.7M. The 52-week trading range was $0.69 to $1.57. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.